Activin Receptors, Type I
"Activin Receptors, Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the two types of ACTIVIN RECEPTORS or activin receptor-like kinases (ALK'S). There are several type I activin receptors. The major active ones are ALK-2 (ActR-IA) and ALK-4 (ActR-IB).
| Descriptor ID |
D030201
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.062.500 D12.776.543.750.750.400.820.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Activin Receptors, Type I".
Below are MeSH descriptors whose meaning is more specific than "Activin Receptors, Type I".
This graph shows the total number of publications written about "Activin Receptors, Type I" by people in this website by year, and whether "Activin Receptors, Type I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 2 | 3 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 2 | 2 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Activin Receptors, Type I" by people in Profiles.
-
Discovery of highly potent and ALK2/ALK1 selective kinase inhibitors using DNA-encoded chemistry technology. Proc Natl Acad Sci U S A. 2024 Nov 19; 121(47):e2413108121.
-
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax. Leukemia. 2024 01; 38(1):82-95.
-
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023 10 10; 7(19):5835-5842.
-
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol. 2021 Apr; 17(12):1449-1458.
-
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020 09 22; 4(18):4282-4291.
-
miR-18a Inhibits BMP4 and HIF-1a Normalizing Brain Arteriovenous Malformations. Circ Res. 2020 10 09; 127(9):e210-e231.
-
Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett. 2018 11 01; 28(20):3356-3362.
-
PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia. Nat Commun. 2016 11 29; 7:13650.
-
Uterine Activin-Like Kinase 4 Regulates Trophoblast Development During Mouse Placentation. Mol Endocrinol. 2015 Dec; 29(12):1684-93.
-
Alk1 and Alk5 inhibition by Nrp1 controls vascular sprouting downstream of Notch. Nat Commun. 2015 Jun 17; 6:7264.